To hear about similar clinical trials, please enter your email below
Trial Title:
Molecularly Aided Stratification for Tumor Eradication Research
NCT ID:
NCT05852522
Condition:
Rare Cancers
Multiomics
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Other
Summary:
NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational
study for biology-guided stratification of adults with rare cancers, including rare
subtypes of common entities, using comprehensive molecular profiling, and clinical
decision-making in a multidisciplinary molecular tumor board.
Criteria for eligibility:
Study pop:
patients from university hospital Heidelberg and all German Consortium for Translation
Research sites
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
Rare cancer (Incidence <6/100,000 persons/year) or Rare subtype of a more common entity
(case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)
Metastatic and/or locally advanced cancer with no curative therapy option and indication
for systemic therapy
Exclusion Criteria:
Severe neurological or psychiatric disorder interfering with the ability to give oral and
written informed consent
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
German Cancer Research Center
Address:
City:
Heidelberg
Zip:
69120
Country:
Germany
Status:
Recruiting
Start date:
November 11, 2018
Completion date:
October 2029
Lead sponsor:
Agency:
German Cancer Research Center
Agency class:
Other
Collaborator:
Agency:
German Consortium for Translational Cancer Research
Agency class:
Other
Source:
German Cancer Research Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05852522
